ImmunoSite Technologies Expands into New Spacious Facility in Miramar // ImmunoSite Technologies

Press Release, February 28, 2013

ImmunoSite Technologies, LLC (IST), a provider of automation, design and customization of complex biological assays to biotechnology and pharmaceutical industries worldwide, announced its relocation to a newly expanded facility at 2831 Corporate Way in Miramar.  With the expansion, the company will be retaining its current 6 employees, making a capital investment of $150,000 and adding 5 new jobs that will focus on product development.

  READ MORE

2013 SLAS 2nd Annual Conference & Exhibition // ImmunoSite Technologies

Executives, Engineers, and Scientists from ImmunoSite Technologies attended the Annual 2013 SLAS meeting in Orlando, Florida and brought back some of the latest technologies to integrate into new automated solutions for biological assay automation that will enhance their client’s productivity even more!

Call IST to discuss your automation needs at (888) 770-4478

Assay Automation Ability - Lyophilized reagents for in vitro whole blood assays // ImmunoSite Technologies

Utility of lyophilized PMA and ionomycin to stimulate lymphocytes in whole blood for immunological assays

Belouski, S. S.*, Wilkinson, J.^, Thomas, J.*, Kelley, K.*, Wang, S.-W.*, Suggs, S.* and Ferbas, J.* (2010), . Cytometry, 78B: 59–64.

doi: 10.1002/cyto.b.20492

The need to implement robust biomarkers in clinical trials has never been greater, and such efforts can be easily compromised by reagent instability or simple human error during assay set-up. Many biotechnology and pharmaceutical companies are introducing efforts to conduct biomarker studies under more rigorous settings, and the use of plates or tubes pre-loaded with stimulation or staining reagents could be of value for studies that involve flow cytometry.

Author Information:

* Amgen Inc., Department of Medical Sciences

^ Beckman Coulter Inc., Custom BioPharma Group, Miami, Florida (author Julie Wilkinson current address is ImmunoSite Technologies, Fort Lauderdale, FL)

Email: John Ferbas (jferbas@amgen.com)

*One Amgen Center Drive, Mailstop 30E-3-C, Thousand Oaks 91320-1799, CA

ImmunoSite Technologies Allies with Goodwin Biotechnology Increasing Capabilities // ImmunoSite Technologies

Working together, companies offer enhanced abilities to develop, test and manufacture biopharmaceuticals

Full release click here

Fort Lauderdale, Fla. – November 1, 2011 – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has entered into a strategic agreement with Goodwin Biotechnology, Inc. (GBI), a full service Contract Manufacturing Organization focused on process development and GMP manufacturing of cell culture derived biopharmaceuticals, based in Plantation, Fla.

READ MORE

ImmunoSite Technologies Aides in Curriculum Development for Employ Florida Banner Center // ImmunoSite Technologies

Cell Culture Course helps Floridians enter, remain and advance in the workforce

Full release click here.

Fort Lauderdale, Fla. – October 18, 2011 – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has helped develop a Cell Culture Workshop that will be offered for the first time October 27 and 28 at the Employ Florida Banner Center for Life Sciences, based at Palm Beach State College’s Eissey Campus in Palm Beach Gardens.

READ MORE

ImmunoSite Technologies Allies with Immudex for More Effective T Cell Response Monitoring // ImmunoSite Technologies

Fort Lauderdale, FL. – ImmunoSite Technologies (IST), LLC, a leading provider of immune monitoring services, has entered into a strategic agreement with Immudex, the sole proprietor of MHC Dextramer^TM technology.

Dextramers are superior reagents for the detection of antigen-specific T cells, having the ability to interact simultaneously with multiple receptors on a single T cell with unsurpassed avidity. The increased avidity of Dextramers compared to conventional MHC multimer reagents enhances resolution and signal-to-noise ratio providing a more accurate assessment of the T cell response, and clearly identifying responses previous generation technologies might miss.

READ MORE

ImmunoSite Technologies Provides Particle Testing Services to Beckman Coulter Customers // Admin

Leading provider of particle testing services now receives referrals of customers seeking particle characterization services from Beckman Coulter, Inc.

Fort Lauderdale, Fla. – April 3, 2011 – ImmunoSite Technologies, LLC, a leading provider of immune monitoring services, is now receiving direct customer referrals for particle testing services from Beckman Coulter, Inc. as part of a recent collaboration agreement. READ MORE